# Bruker (BRKR) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BRKR/thesis · /stocks/BRKR/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
title: Financial Quality & Adversarial Sweep
ticker: BRKR
company: Bruker Corporation
date: 2026-06-10
---

### Step 04 — Financial Quality: Bruker Corporation (BRKR)

*Note: No earnings transcript analysis performed. Financial quality analysis based on SEC filings, XBRL data, and web research (coverage-next-full path).*

#### 1. Statement Quality Assessment

##### Income Statement

**Fundamental issue:** Bruker's GAAP income statement is materially distorted by acquisition-related charges, rendering GAAP EPS unrepresentative of cash earnings power. [S1]

| Adjustment Category | FY2025 Estimated Magnitude | GAAP Impact |
|--------------------|--------------------------|------------|
| Amortization of acquired intangibles | ~$130–160M | Increases COGS and SG&A; depresses gross profit and operating income |
| Restructuring charges | ~$30–50M | Reduces operating income |
| Acquisition/transaction costs | ~$15–25M | Reduces operating income |
| SBC (non-cash) | $23.7M | Reduces net income |
| Preferred dividends | ~$40M | Reduces income available to common holders |
| **Total above-GAAP adjustments (est.)** | **~$240–300M** | GAAP EPS -$0.15 → Non-GAAP EPS +$1.83 = ~$2.00/share adjusted |

**Non-GAAP reconciliation:** The ~$2/share gap between GAAP (-$0.15) and non-GAAP ($1.83) EPS is dominated by intangible amortization from ELITechGroup and NanoString acquisitions. This is a real, recurring cash cost that will continue for 7–12 years at declining rates. However, non-GAAP EPS is still informative because the cash being "spent" is past M&A purchase price, not ongoing operational expense. The appropriate valuation framing is EV/EBITDA (which is post-D&A but pre-interest) or non-GAAP EPS adjusted for maintenance CapEx. [S1]

##### Balance Sheet Quality

**Goodwill & Intangibles Concentration:**
- Goodwill: $1.548B (24.8% of total assets)
- Intangibles: ~$900M (est. ~14.4% of total assets)
- **Combined: ~$2.45B = ~39% of total assets** [S2]

This is elevated vs. organic peers (Waters: ~25–30%; Agilent: ~20–25%) but expected given FY2024 acquisition spree. The risk is impairment if acquired businesses underperform. NanoString was acquired at a distressed price (~$393M for a company that was SPAC-born and cash-constrained); impairment risk is lower there than for ELITechGroup (full-price strategic acquisition at peak leverage).

**Inventory quality:** Bruker carries ~$800–900M inventory (estimated from current assets). Instrument-company inventory tends to be high-value work-in-progress with low obsolescence risk, but integration inventory management is a watch item.

**Convertible Preferred Dilution:** Bruker issued preferred equity in 2024. The preferred carries ~$40M/year cash dividend and may convert to common shares, creating dilution risk. This reduces FCF available to common holders and is a hidden leverage instrument. [S3]

##### Cash Flow Statement Quality

**OCF → FCF compression:**

| Year | OCF | CapEx | FCF | FCF/Non-GAAP EPS |
|------|-----|-------|-----|-----------------|
| FY2022 | $274M | $129M | $145M | ~73% |
| FY2023 | $350M | $107M | $243M | ~82% |
| FY2024 | $251M | $115M | $136M | ~38% |
| FY2025 | $134M | $91M | $43M | ~15% |

**FCF conversion collapsed from ~80% (FY2022–2023) to ~15% (FY2025).** This is a material concern. Causes: [S2]
1. Working capital build during integration (increased receivables and inventory)
2. Higher cash interest expense (~$90M vs. ~$20M pre-acquisition)
3. Integration-related cash charges (not fully captured in non-GAAP add-backs)
4. Preferred dividends (~$40M)

**Recovery thesis requirement:** FCF must recover to $150–200M+ range (FY2026–FY2027) to be sustainable. Company targets FCF improvement as part of Project Accelerate 3.0 cost saves + working capital normalization.

#### 2. Key Financial Ratios

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|--------|--------|--------|--------|--------|-------|
| Gross Margin | 51.6% | 51.0% | 49.0% | 45.9% | Declining ↓ |
| GAAP Operating Margin | 17.1% | 14.7% | 7.5% | 2.0% | Declining ↓ |
| Non-GAAP Operating Margin (est.) | ~17% | ~16–17% | ~13–14% | ~12% | Declining |
| GAAP Net Margin | 11.7% | 14.4% | 3.4% | -0.3% | — |
| ROE (GAAP) | 27.8% | 34.4% | 6.8% | -0.4% | — |
| ROIC (est., GAAP) | ~13% | ~15% | ~5% | ~2-3% | Declining ↓ |
| Net Debt/EBITDA | ~1.1x | ~1.4x | ~4.4x | ~5.4x | Elevated ↑ |
| R&D/Revenue | 9.3% | 9.9% | 11.2% | 11.5% | Stable/rising |
| FCF Margin | 5.7% | 8.2% | 4.0% | 1.3% | Declining ↓ |

[S2]

#### 3. Financial Strength Assessment

**Positives:**
- R&D investment is consistent and growing (11.5% of revenue); moat maintenance is funded
- Revenue scale crossed $3.4B; fixed cost leverage on recovery
- Gross margin at 45.9% is below Bruker's historical capability (~50–52%) but the business earns above average gross margins vs. general manufacturing
- Q1 2026: $71M OCF showing early signs of working capital normalization

**Negatives / Concerns:**
- Net Debt/EBITDA at ~5.4x is highly elevated and unsustainable long-term
- GAAP earnings power is essentially zero; all earnings are non-GAAP construct
- Preferred dividend (~$40M) is a cash outflow not visible in traditional non-GAAP metrics
- CapEx is sticky at $90–130M/year even as OCF compressed

#### 4. Adversarial Research Sweep

*This section covers short seller reports, accounting concerns, regulatory investigations, and adverse legal proceedings.*

##### Finding 1: Securities Class Action Investigation (Active) — MEDIUM RISK

**Status:** Multiple plaintiff law firms (Levi & Korsinsky, Rosen Law) are investigating whether Bruker Corporation and its officers violated federal securities laws during the period approximately August 2024 through July 2025. [S3]

**Alleged conduct:** Bruker guided for strong revenue growth in August 2024 earnings call, but then issued a Q2 2025 preliminary announcement showing organic revenue declined -7%. Plaintiffs allege management had material adverse information about demand deterioration (NIH funding cuts impact, China slowdown) that was not timely disclosed.

**Current status:** Pre-litigation investigation stage. No formal complaint filed as of June 2026. No SEC enforcement action identified.

**Assessment [Judgment]:** Pre-filing investigations frequently fail to materialize as filed complaints. Even if filed, instrument company securities class actions tend to settle in the $10–50M range, which would be immaterial relative to Bruker's balance sheet. Management was arguably caught by a faster-than-anticipated funding environment change rather than deliberately misleading. However, this is a monitoring risk that could generate headline noise. We rate it MEDIUM risk but not a thesis-changer.

##### Finding 2: No Dedicated Short Seller Report Found — LOW RISK

**Status:** No published short report from named activist short sellers (Hindenburg, Citron, Spruce Point, Bleecker Street) identified targeting BRKR. The stock's 60%+ decline from $109 (2022 high) to $29 (52-week low) was driven by fundamental concerns (leverage, organic slowdown), not short-seller campaigns. [S3]

##### Finding 3: 10x Genomics Patent Dispute — RESOLVED / LOW RISK

**Status:** 10x Genomics sued Bruker's NanoString subsidiary for patent infringement related to spatial biology technologies. Key outcome: The primary '989 patent (10x's core claim) was invalidated by the German Federal Patent Court (May 2024) and the European Unified Patent Court (October 2024). US proceedings still pending but with significantly weakened 10x position. [S3]

**Assessment [Judgment]:** Substantially resolved in Bruker/NanoString's favor. Risk of injunction on CosMx sales has materially diminished. Remaining US proceedings are monitoring items, not strategic threats.

##### Finding 4: Governance Concentration — STRUCTURAL, NOT ADVERSARIAL

**Note:** Laukien family ~73% voting control is a disclosed, permanent governance feature. This is a standard governance discount consideration, not an adversarial finding. The family's economic ownership aligns interests with minority shareholders. [S4]

##### Finding 5: NanoString Historical Accounting — LOW RISK

**Status:** NanoString was a SPAC-era company with a history of significant operating losses and going-concern risk before Bruker's acquisition. No restatements identified. Post-acquisition, NanoString is subsumed into BSI CALID; any legacy accounting irregularities would be limited to the pre-acquisition period and are not Bruker's liability.

#### 5. Source Index

| ID | Source |
|----|--------|
| [S1] | other/stockanalysis_summary.md; xbrl/xbrl_summary.md |
| [S2] | xbrl/xbrl_summary.md; derived calculations |
| [S3] | other/adversarial_research.md; other/recent_news.md |
| [S4] | proxy/governance_and_compensation.md |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BRKR/fundamental

## Navigation

- Overview: /stocks/BRKR
- Financials (this page): /stocks/BRKR/financials
- Thesis: /stocks/BRKR/thesis
- Investment Memo: /stocks/BRKR/memo
- Coverage universe: /stocks